{"id":"NCT03745651","sponsor":"Incyte Corporation","briefTitle":"TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis","officialTitle":"Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-20","primaryCompletion":"2019-11-18","completion":"2020-11-09","firstPosted":"2018-11-19","resultsPosted":"2021-12-17","lastUpdate":"2023-09-28"},"enrollment":618,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Ruxolitinib cream","otherNames":["INCB018424 phosphate cream"]},{"type":"DRUG","name":"Vehicle cream","otherNames":[]}],"arms":[{"label":"Vehicle Control (VC) Period: Vehicle Cream BID","type":"PLACEBO_COMPARATOR"},{"label":"VC Period: Ruxolitinib 0.75% Cream BID","type":"EXPERIMENTAL"},{"label":"VC Period: Ruxolitinib 1.5% Cream BID","type":"EXPERIMENTAL"},{"label":"Long-Term Safety (LTS) Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID","type":"EXPERIMENTAL"},{"label":"LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID","type":"EXPERIMENTAL"},{"label":"LTS Period: Ruxolitinib 0.75% Cream BID","type":"EXPERIMENTAL"},{"label":"LTS Period: Ruxolitinib 1.5% Cream BID","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy of ruxolitinib cream in adolescents and adults with atopic dermatitis (AD).","primaryOutcome":{"measure":"VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8","timeFrame":"Baseline to Week 8","effectByArm":[{"arm":"VC Period: Vehicle Cream BID","deltaMin":7.6,"sd":null},{"arm":"VC Period: Ruxolitinib 0.75% Cream BID","deltaMin":39,"sd":null},{"arm":"VC Period: Ruxolitinib 1.5% Cream BID","deltaMin":51.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"},{"comp":"OG000 vs OG002","p":"< 0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":11},"locations":{"siteCount":66,"countries":["United States","Bulgaria","Canada","Czechia","Germany","Poland","Spain"]},"refs":{"pmids":["39546129","39375281","38995504","38698175","36574595","36264430","33982267","33957195","33658996"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217471&amp;parentIdentifier=INCB%2018424-304&amp;attachmentIdentifier=061851fa-a439-4436-8d9f-0b252f3007e6&amp;fileName=INCB18424-304_Plain_Language_Summary.pdf&amp;versionIdentifier=90e1fe05-9680-4580-ab7d-6aadf96820fd"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":124},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Application site pain"]}}